• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

ADA 2017: Oral Agents Under Review

Slideshow
Conference|ADA

When to start screening for B12 deficiency in your diabetes patients taking metformin? We review a dose-response diet study plus 2 others on oral drugs.

During the general poster sessions at the American Diabetes Association (ADA) 77th Scientific Sessions, several of the work-horse oral antihyperglycemic agents were highlighted in studies that looked at B12 deficiency with metformin therapy; adherence with different glimepiride regimens as assessed by an electronic monitoring system; and, the efficacy of a fixed-dose combination vs that of the individual components.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
American Liver Foundation Announces First Federally-Funded Research on MASLD / image credit American Liver Foundation Lorraine Stiehl

American Liver Foundation Announces First Federally-Funded Research on MASLD

April 26th 2024
Article

The national study on the true prevalence of metabolic dysfunction-associated liver disease is essential to screening, prevention, and treatment efforts, says AFL CEO Stiehl.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

ACP issues guidelines on newer pharmacologic treatment for adults with type 2 diabetes/ image credit: medication pens:©felipecaparros/stock.adobe.com

ACP Recommends SGLT2i, GLP1 RA After Metformin to Manage Cardiorenal Comorbidities in Adults with Type 2 Diabetes

April 22nd 2024
Article

Based on the classes' cardio- and renoprotective benefits, the ACP recommends SGLT2i and GLP1RA as second-line therapy in adults with T2D who are most likely to benefit.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

July 22nd 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

Semaglutide Improves Functional Status, Body Weight in Patients with HFpEF, Obesity, T2D: Daily Dose / image credit: ©New Africa/AdobeStock

Semaglutide Improves Functional Status, Body Weight in Patients with HFpEF, Obesity, T2D: Daily Dose

April 15th 2024
Article

Your daily dose of the clinical news you may have missed.

Semaglutide 2.4 mg Improves Functional Status, Body Weight in Adults with HFpEF, Obesity, T2D / image Mikhail Kosiborod, MD St Luke's Mid America Heart institute

Semaglutide 2.4 mg Improves Functional Status, Body Weight in Adults with HFpEF, Obesity, T2D

April 8th 2024
Article

ACC.24: Results of STEP HFpEF DM showed significant improvement in quality of life measures among adults with obesity-related HFpEF and type 2 diabetes.

© 2024 MJH Life Sciences

All rights reserved.